Raedler T J, Bymaster F P, Tandon R, Copolov D, Dean B
Department of Psychiatry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mol Psychiatry. 2007 Mar;12(3):232-46. doi: 10.1038/sj.mp.4001924. Epub 2006 Dec 5.
Although the neurotransmitter dopamine plays a prominent role in the pathogenesis and treatment of schizophrenia, the dopamine hypothesis of schizophrenia fails to explain all aspects of this disorder. It is increasingly evident that the pathology of schizophrenia also involves other neurotransmitter systems. Data from many streams of research including pre-clinical and clinical pharmacology, treatment studies, post-mortem studies and neuroimaging suggest an important role for the muscarinic cholinergic system in the pathophysiology of schizophrenia. This review will focus on evidence that supports the hypothesis that the muscarinic system is involved in the pathogenesis of schizophrenia and that muscarinic receptors may represent promising novel targets for the treatment of this disorder.
尽管神经递质多巴胺在精神分裂症的发病机制和治疗中起着重要作用，但精神分裂症的多巴胺假说并不能解释该疾病的所有方面。越来越明显的是，精神分裂症的病理也涉及其他神经递质系统。来自包括临床前和临床药理学、治疗研究、尸检研究和神经影像学等多个研究领域的数据表明，毒蕈碱胆碱能系统在精神分裂症的病理生理学中起着重要作用。本综述将聚焦于支持以下假说的证据：毒蕈碱系统参与精神分裂症的发病机制，且毒蕈碱受体可能是治疗该疾病的有前景的新靶点。
